Previous 10 | Next 10 |
A Phase 3 clinical trial, SOTA-EMPA , evaluating Lexicon Pharmaceuticals' (NASDAQ: LXRX ) Zynquista (sotagliflozin) in patients with type 2 diabetes (T2D) met the primary endpoint demonstrating its superiority versus placebo in lowering HbA1C levels at week 26. More news on: Lexicon Pha...
THE WOODLANDS, Texas, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline data from the Phase 3 SOTA-EMPA study for sotagliflozin (Zynquista™) in type 2 diabetes. The topline results are as follows: Sotagliflozin 400 mg achi...
December 9, 2019 Palm Beach, FL –December 9, 2019 – One of the latest market reports in the published by Credence Research, Inc. shows that the Multiple Myeloma Treatment market, which was valued at USD $8,398.3 Mn in 2016, is expected to reach USD $21,221.8 Mn ...
Are These On Your List Of Penny Stocks To Watch In December? No matter if you trade blue-chip stocks or penny stocks , you need the right stock market education to understand what you’re actually looking at. Without understanding how to invest, let alone day trade, the stock market...
Lexicon Pharmaceuticals ( LXRX +4% ) is up on a 20x surge in volume on the heels of positive results from a Phase 1 multiple ascending-dose clinical trial evaluating neuropathic pain candidate LX9211 in healthy volunteers. More news on: Lexicon Pharmaceuticals, Inc., Healthcare stocks ...
Sage Therapeutics SAGE -62% after SAGE-217 flunks MDD study. More news on: Capricor Therapeutics, Inc., Axsome Therapeutics, Inc., Lexicon Pharmaceuticals, Inc., Stocks on the move, Read more ...
THE WOODLANDS, Texas, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced positive topline data from the Phase 1 multiple ascending dose study of LX9211, a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1), in developm...
Lexicon Pharmaceuticals ( LXRX +5.7% ) is up, albeit on below-average volume, on the heels of a safety review of the initial run-in cohort in a Phase 2 clinical trial, TELE-ABC , evaluating telotristat ethyl, combined with first-line chemo, for the treatment of patients with advanced bi...
THE WOODLANDS, Texas, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the completion of a safety review of the initial run-in cohort of the Tel otristat E thyl for A dvanced B iliary Tract C ancer, or TELE-ABC, study, which is a ...
Monday wasn't a good day on Wall Street, as major benchmarks started the final month of 2019 with across-the-board declines. The White House reignited trade disputes by taking away a previous exemption to steel tariffs for imports from Brazil and Argentina, and market watchers wondered what migh...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings consistent with two peer-reviewed studies published in June 2024 THE WOODLANDS, Texa...